Quizartinib
Quizartinib (pronounced as kwi-zar-ti-nib) is a type of antineoplastic agent specifically classified as a tyrosine kinase inhibitor. It is primarily used in the treatment of acute myeloid leukemia (AML).
Etymology
The name "Quizartinib" is derived from the systematic International Union of Pure and Applied Chemistry (IUPAC) nomenclature. It is a combination of parts of the chemical name "Quinazoline" and "Tyrosine Kinase Inhibitor".
Usage
Quizartinib is used in the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) which is FLT3-ITD positive. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, helping to slow down the growth of these cells.
Related Terms
- Antineoplastic agent: A substance that inhibits or prevents the proliferation of neoplasms (abnormal growth of tissue).
- Tyrosine kinase inhibitor: A pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades.
- Acute myeloid leukemia (AML): A cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood.
- FLT3: FMS-like tyrosine kinase 3, a protein that, in humans, is encoded by the FLT3 gene. Mutations to this gene are often associated with acute myeloid leukemia.
See Also
External links
- Medical encyclopedia article on Quizartinib
- Wikipedia's article - Quizartinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski